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Abstract
Purpose: To evaluate the long-term efficacy of hydrophilic and lipophilic statin therapy for cardiovascular outcomes in Asian
diabetic patients.
Method: Newly diagnosed cases of type 2 diabetes during the period from January 2000 to December 2011 were divided into 2
cohorts on the basis of their statin use, namely hydrophilic statin and lipophilic statin. We used Cox proportional hazard
regression models to analyze the risks of cardiovascular outcomes.
Result: In this study, 12 896 patients used statin, including 4259 patients using hydrophilic statin and 8637 patients using lipophilic
statin. With 12-year follow-up, higher incidence rate of coronary artery disease and stroke was noted in the lipophilic statin use
instead of hydrophilic statin use.
Conclusion: According to our long-term cohort study, hydrophilic statin use may be a better choice than lipophilic statin to
reduce cardiovascular events in Asian diabetic patients.
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Introduction
Statins are hydroxymethylglutaryl-CoA reductase inhibitors,
widely prescribed for various types of dyslipidemia to reduce
cardiovascular risk. Most clinical guidelines recommend statin
use for primary and secondary cardiovascular prevention or
treatment.1,2 Diabetes is one of the high-risk factors for cardi-
ovascular disease, as is stated in clinical guidelines.1,2 One
study published in 1998 showed that diabetes can be considered
as a myocardial infarction or a risk equivalent state.3 A review
article presented the links between diabetes and cardiovascular
disease.4 Consistent with the findings of these studies, statins
have been prescribed for diabetic patients worldwide. How-
ever, there are numerous subtypes of statin exhibiting structural
differences, and these differences cause various pharmacoki-
netics or efficacy. In general, statins are classified into hydro-
philic or lipophilic groups on the basis of tissue selectivity. In
our studies, there were rosuvastatin and pravastatin in the
hydrophilic group and there were atorvastatin, simvastatin,
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fluvastatin, and lovastatin in the lipophilic group. No standard
recommendations exist for selecting a hydrophilic or lipophilic
statin in clinical practice. Our 12-year follow-up study was
designed to enable evaluating the benefits of hydrophilic or
hydrophobic statins for diabetic patients in Asia.
Methods
Data Source
The universal National Health Insurance (NHI) program was
implemented in Taiwan in March 1995 as a compulsory single-
payer health-care system. By 2011, it had achieved a coverage
rate of approximately 99.9% of the 23.22 million Taiwanese
citizens.5,6 The substantial computerized database that became
the National Health Insurance Research Database (NHIRD)
was derived from the NHI program and is maintained by the
National Health Research Institutes. The identification num-
bers of all people in the NHIRD are encrypted to protect pri-
vacy. In this study, we used the data set from the Longitudinal
Health Insurance Database 2000 (LHID2000). It contains the
original claims data of 1 000 000 claims, randomly sampled
from the 2000 Registry for Beneficiaries of the NHIRD, which
has been demonstrated to be representative of the entire popu-
lation. Patient diagnoses were coded according to the Interna-
tional Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM). Taiwan launched an NHI in
1995, operated by a single buyer, the government. Medical
reimbursement specialists and peer review should scrutinize
all insurance claims. The diagnoses of cardiovascular events
were based on the ICD-9 codes which were judged and deter-
mined by related specialists and physicians according to the
standard clinical criteria. Therefore, the diagnoses and codes
for cardiovascular events used in this study should be correct
and reliable.
Ethics Statement
The NHIRD encrypts patient personal information to protect
privacy and provides researchers with anonymous identifica-
tion numbers associated with relevant claims information,
including sex, date of birth, medical services received, and
prescriptions. Therefore, patient consent is not required to
access the NHIRD. This study was approved to fulfill the con-
dition for exemption by the institutional review board (IRB) of
China Medical University (CMUH-104-REC2-115-CR4). The
IRB also specifically waived the consent requirement.
Sampled Participants
Figure 1 shows the selection process of the participants in the
study cohorts. The study patients were identified from the
Figure 1. Selection process of the participants in the study cohorts.
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LHID2000 as newly diagnosed cases with type 2 diabetes mel-
litus (T2DM; ICD-9-CM 250.x0 and 250.x2) during the period
from January 2000 to December 2011. The patients with
T2DM were divided into 2 cohorts according to their statin
use: the hydrophilic statin cohort included patients who had
received hydrophilic statin therapy for at least 6 months (180
days) and the lipophilic statin cohort included patients who had
received lipophilic statin therapy for at least 6 months (180
days). Among the 2 cohorts, patients with a history of coronary
artery disease (CAD; ICD-9-CM codes 410-414), acute myo-
cardial infarction (AMI; ICD-9-CM code 410), congestive
heart failure (CHF; ICD-9-CM code 428), atrial fibrillation
(AF; ICD-9-CM code 427.31), and stroke (ICD-9-CM codes
430-438) before the index date, patients under 20 years of age,
and those with incomplete medical information were excluded.
Outcome
Cardiovascular events included CAD, AMI, CHF, AF, and
stroke. All study patients were followed from the index
date to the development of cardiovascular events, loss to
follow-up, withdrawal from the insurance program, or
December 31, 2011.
Baseline Variables
We obtained baseline variables investigated in this study,
including sociodemographic status (including sex, age,
monthly income, and urbanization level), comorbidities of
hypertension (ICD-9-CM codes 401 to 405), chronic obstruc-
tive pulmonary disease (ICD-9-CM codes 491, 492, 496),
chronic kidney disease (ICD-9-CM codes 580-589), and
arrhythmia (ICD-9-CM code 426, 427), and medications
including angiotensin-converting enzyme inhibitors, angio-
tensin II receptor blockers, b-blockers, metformin, aspirin,
and insulin.
Statistical Analysis
We compared the distributions of sociodemographic status,
comorbidities, and medications between the cohorts with
hydrophilic statin and with lipophilic statin use by using a
Pearson w2 test for categorical variables and a Student t test
for continuous variables. The overall sex-specific incidence
densities of cardiovascular events were measured among the
2 cohorts. Univariable and multivariable Cox proportional
hazards regression models were used to estimate hazard ratios
(HRs) and 95% confidence intervals (CIs) for cardiovascular
events in patients with T2DM with lipophilic statin use in
relationship to the hydrophilic statin use. The multivariable
models simultaneously adjusted for sociodemographic status,
comorbidities, and medications. The cumulative incidence of
cardiovascular events among the 2 cohorts was plotted using
the Kaplan-Meier method and the difference was tested using a
log-rank test. All data analyses were performed using SAS 9.3
software (SAS Institute, Cary, North Carolina) for Windows.
The level of significance was set at .05, and the tests were
2-tailed.
Results
This study involved4259patientswhousedhydrophilic statin and
8637 patients who used lipophilic statin (Table 1). Among the 2
cohorts, most patients were aged 50 to 64 years (50.7% in the
hydrophilic statin use cohort and 49.4% in the lipophilic statin use
cohort) and were female (52.6% in the hydrophilic statin use
cohort and 52.1% in the lipophilic statin use cohort). Compared
with patients in the lipophilic statin cohort, the patients in the
Table 1. Comparison of Demographics and Comorbidity Between
Hydrophilic and Lipophilic Statin Use.a
Type 2 Diabetes
P Value
Hydrophilic
Statin Use
(N ¼ 4259)
Lipophilic
Statin Use
(N ¼ 8637)
n % n %
Age, years .001
49 919 21.6 2103 24.4
50-64 2158 50.7 4264 49.4
>65 1182 27.8 2270 26.3
Mean (SD)b
Gender .59
Women 2240 52.6 4499 52.1
Men 2019 47.4 4138 47.9
Monthly income (NTD) .027
<15 000 766 18.0 1604 18.6
15 000-19 999 2031 47.7 4272 49.5
20 000 1462 34.3 2761 32.0
Urbanization levelc <.001
1 (highest) 1422 33.4 2667 30.9
2 1336 31.4 2600 30.1
3 770 18.1 1479 17.1
4 731 17.2 1891 21.9
Comorbidity
Hypertension 2951 69.3 5651 65.4 <.001
COPD 480 11.3 956 11.1 .73
CKD 578 13.6 1106 12.8 .22
Arrhythmia 242 5.68 470 5.44 .57
Medications
ACEI 2157 50.7 4106 47.5 <.001
AIIRBs 1939 45.5 2880 33.3 <.001
b-Blockers 2240 52.6 4311 49.9 .004
Metformin 3518 82.6 6894 79.8 <.001
Aspirin 1778 41.8 3197 37.0 <.001
Insulin 2591 60.8 5074 58.8 <.001
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; AIIRB, angio-
tensin II receptor blocker; COPD, chronic obstructive pulmonary disease;
CKD, chronic kidney disease; NTD, new Taiwan dollar; SD, standard deviation.
aChi-square test comparing subjects with hydrophilic statin use and lipophilic
statin use.
bT test.
cThe urbanization level was categorized by the population density of the resi-
dential area into 4 levels, with level 1 as the most urbanized and level 4 as the
least urbanized.
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hydrophilic statin cohort exhibited a higher tendency to have high
monthly incomes (34.3% vs 32.0% formonthly income20000)
and live in urbanized areas (64.8% vs 61.0% in urbanization
levels 1 and 2). Comorbidities were more prevalent in the hydro-
philic statin cohort than in the lipophilic statin cohort, particularly
hypertension (69.3% vs 65.4%). The prevalence of medications
was higher in the hydrophilic statin cohort than in the lipophilic
statin cohort.
With 12-year follow-up, Kaplan-Meier analysis was adopted
to calculate the cumulative incidence of CAD, AMI, CHF, and
stroke, as shown in Figure 1. The cumulative incidence of CAD
and stroke was higher in patients of the lipophilic statin cohort
than in those of the hydrophilic statin cohort (Figure 2A, log-
rank test: P < .001, Figure 2D, log-rank test: P < .001).
The overall incidences of CAD were 21.6 and 31.6 per 1000
person-years in the hydrophilic statin and lipophilic statin
cohorts, respectively (Table 2). After adjusting for age, sex,
comorbidities, and medication, the risk of CAD and stroke in
the lipophilic statin use cohort was 54% and 46% higher (sig-
nificantly) than in the hydrophilic statin use cohort. Among
men patients, the risk of CAD in the lipophilic statin use
cohort was 49% higher (significantly) than in the hydrophilic
statin use cohort. Among women patients, the risk of CAD,
CHF, and stroke in the lipophilic statin use cohort was 58%,
43%, and 66% higher (significantly) than in the hydrophilic
statin use cohort.
The risk of CADwas higher in men with lipophilic statin use
(HR ¼ 1.74, 95% CI ¼ 1.43-2.11) and women with lipophilic
statin use (HR ¼ 1.58, 95% CI ¼ 1.31-1.91) than in women
with hydrophilic statin use (Table 3). Compared with women
who used hydrophilic statin, men who used lipophilic
statin exhibited a higher risk of AMI (HR ¼ 1.74, 95%
Figure 2. Cumulative incidences of coronary artery disease (A), acute myocardial infarction (B), congestive heart failure (C), and stroke (D) in
patients with hydrophilic statin use, and with lipophilic statin use, compared to patients without statin use.
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CI ¼ 1.04-2.91). Compared with women who used hydrophi-
lic statin, men who used lipophilic statin were 1.87-fold
more likely to develop stroke (95% CI ¼ 1.44-2.43),
followed by women who used lipophilic statin (HR ¼
1.66, 95% CI ¼ 1.29-2.14) and men who used lipophilic
statin (HR ¼ 1.48, 95% CI ¼ 1.07-2.05).
Table 2. Comparisons of Incidence Densities and Hazard Ratio of Cardiovascular Outcomes in Study Cohorts.
Hydrophilic Statin Use
Crude HRb
(95% CI)
Adjusted HRc
(95% CI)
Lipophilic Statin Use
Crude HRb
(95% CI)
Adjusted HRc
(95% CI)Case Ratea Case Ratea
All
CAD 262 21.6 1 (Reference) 1 (Reference) 1000 31.6 1.48 (1.29-1.69)d 1.54 (1.35-1.77)d
AMI 41 3.19 1 (Reference) 1 (Reference) 140 3.98 1.12 (0.79-1.60) 1.12 (0.79-1.59)
CHF 113 8.93 1 (Reference) 1 (Reference) 373 10.8 1.18 (0.96-1.46) 1.23 (0.99-1.52)
AF 28 2.17 1 (Reference) 1 (Reference) 92 2.61 1.11 (0.72-1.69) 1.15 (0.75-1.76)
Stroke 147 11.7 1 (Reference) 1 (Reference) 560 16.5 1.39 (1.16-1.67)d 1.46 (1.22-1.76)d
Men
CAD 121 22.1 1 (Reference) 1 (Reference) 461 31.2 1.44 (1.17-1.76)d 1.49 (1.22-1.83)d
AMI 22 3.82 1 (Reference) 1 (Reference) 73 4.48 1.07 (0.66-1.74) 1.06 (0.65-1.72)
CHF 53 9.31 1 (Reference) 1 (Reference) 145 9.03 0.95 (0.69-1.30) 0.99 (0.72-1.36)
AF 14 2.42 1 (Reference) 1 (Reference) 40 2.44 0.88 (0.47-1.62) 0.92 (0.50-1.72)
Stroke 73 13.0 1 (Reference) 1 (Reference) 253 16.1 1.21 (0.93-1.58) 1.26 (0.97-1.64)
Women
CAD 141 21.2 1 (Reference) 1 (Reference) 539 32.0 1.52 (1.26-1.83)d 1.58 (1.31-1.90)d
AMI 19 2.68 1 (Reference) 1 (Reference) 67 3.55 1.17 (0.70-1.95) 1.18 (0.70-1.98)
CHF 60 8.61 1 (Reference) 1 (Reference) 228 12.4 1.40 (1.06-1.87)e 1.43 (1.07-1.91)e
AF 14 1.97 1 (Reference) 1 (Reference) 52 2.75 1.33 (0.74-2.42) 1.36 (0.74-2.48)
Stroke 74 10.7 1 (Reference) 1 (Reference) 307 17.0 1.57 (1.22-2.03)d 1.66 (1.29-2.15)d
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; AIIRB, angiotensin II receptor blocker; AMI, acute myocardial infarction;
CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney
disease; HR, hazard ratio.
aRate, incidence rate, per 1000 person-years.
bCrude HR, relative hazard ratio.
cAdjusted HR: Multivariable analysis including age, sex, monthly income, urbanization level, comorbidity of hypertension, COPD, CKD, and arrhythmia, and
medication of ACEI, AIIRB, b-blockers, metformin, aspirin, and insulin.
dP < .001.
eP < .05.
Table 3. Development of CAD, AMI, and Stroke in Patients With Statin Use Associated With Gender in Cox Regression Analysis.
Hydrophilic Statin Use Lipophilic Statin Use Gender N Case Ratea Crude HRb (95% CI) Adjusted HRc (95% CI)
CAD
Yes No Women 2240 141 21.2 1 (Reference) 1 (Reference)
Yes No Men 2019 121 22.1 1.04 (0.82-1.32) 1.16 (0.91-1.48)
No Yes Women 4499 539 32.0 1.52 (1.27-1.83)d 1.58 (1.31-1.91)d
No Yes Men 4138 461 31.2 1.48 (1.23-1.79)d 1.74 (1.43-2.11)d
AMI
Yes No Women 2240 19 2.68 1 (Reference) 1 (Reference)
Yes No Men 2019 22 3.82 1.48 (0.80-2.73) 1.65 (0.89-3.07)
No Yes Women 4499 67 3.55 1.20 (0.72-2.00) 1.19 (0.71-1.99)
No Yes Men 4138 73 4.48 1.55 (0.93-2.57) 1.74 (1.04-2.91)e
Stroke
Yes No Women 2240 74 10.7 1 (Reference) 1 (Reference)
Yes No Men 2019 73 13.0 1.22 (0.89-1.69) 1.48 (1.07-2.05)e
No Yes Women 4499 307 17.0 1.57 (1.21-2.02)d 1.66 (1.29-2.14)d
No Yes Men 4138 253 16.1 1.49 (1.15-1.93)e 1.87 (1.44-2.43)d
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; AIIRB, angiotensin II receptor blocker; AMI, acute myocardial infarction; CAD, coronary artery
disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; HR, hazard ratio.
aRate, incidence rate, per 1,000 person-years.
bCrude HR, relative hazard ratio.
cAdjusted HR: multivariable analysis including age, sex, monthly income, urbanization level, comorbidity of hypertension, COPD, CKD, and arrhythmia, and
medication of ACEI, AIIRB, b-blockers, metformin, aspirin, and insulin.
dp < 0.001.
ep < 0.05 .
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Discussion
In our study, we separated 2 statin group cohorts including
hydrophilic statin cohort such as rosuvastatin and pravastatin
users and lipophilic statin cohort such as atorvastatin, simvas-
tatin, fluvastatin, and lovastatin users. Patients in the hydrophi-
lic statin cohort were mostly older than 50 years old, female,
had a high monthly income, lived in urbanized areas, and
exhibited comorbidities with hypertension. Multiple medica-
tions such as antihypertension, oral antidiabetic agents, and
insulin were prescribed in our hydrophilic statin cohort.
Sex and Hydrophilic or Lipophilic Statin
The Cholesterol Treatment Trialists’ Collaboration suggested
that statin therapy is of similar effectiveness in the prevention
of major vascular events among men and women.7 One study
showed that high low-density lipoprotein (LDL) cholesterol lev-
els were significantly associated with cardiovascular events
among men and women, but there was a stronger association for
stroke in women and for coronary heart disease death in men.8 In
our study, most cardiovascular events such as CAD and stroke in
patients used lipophilic statin. Among men patients, the risk of
CAD in the lipophilic statin use cohort was significantly higher
than other men in the hydrophilic statin use cohort.
Among women patients, the risk of CAD, CHF, and stroke
in the lipophilic statin use cohort was significantly higher than
other women in the hydrophilic statin use cohort. Different
races or hormone effects in women are possible explanations.
We suggest that hydrophilic statin may be the optimal choice
for diabetic Asian for reducing the occurrence of cardiovascu-
lar events.
Hydrophilic or Lipophilic Statins for Cardiovascular
Events
In our study, no benefit was observed for AF in diabetic
patients of both statin cohorts. Atrial fibrillation is another
independent risk factor for cardiovascular death.9 However,
previous studies have shown that lipophilic statin with atorvas-
tatin was superior to hydrophilic statin with pravastatin on AF
issue.10 Statin therapy for CHF was considered controversial in
other studies.11,12 In our study, no benefit was observed in both
statin cohorts and both sexes. A 2-year comparison of hydro-
philic and lipophilic statin studies showed no significant dif-
ference in AMI.13 A 1-year cardiovascular outcomes study
suggested that lipophilic statin was superior for AMI.14 How-
ever, another study showed that hydrophilic statin was superior
to lipophilic statin in the prevention of new-Q wave formation
in patients with AMI.15 Our long-term study showed that
hydrophilic statin was superior to lipophilic statin in diabetic
patients with CAD, and stroke.
Hydrophilic Versus Lipophilic Statins
In our study, the incidence of CAD and stroke was strongly
associated in the lipophilic statin cohort; for the male group, the
incidences of CAD were higher in the lipophilic statin cohort,
but for the female group, the incidences of CAD, CHF, and
stroke were higher in the lipophilic statin cohort. In addition to
a lipid-lowering effect, numerous pleiotropic effects are asso-
ciated with statin use, such as a reduction in inflammation
and vascular thrombus and an improvement in endothelial
functions.16-18 Hydrophilic statin exhibits lower tissue absorp-
tion and lower dependence on the cytochrome P450 enzyme
compared with lipophilic statin; therefore, fewer side effects
occur in the use of hydrophilic statin.19 According to one study,
compared with lipophilic statin, hydrophilic statin was superior
in attenuating inflammation.20 These are the possible mechan-
isms explaining our cardiovascular outcomes. The retrospec-
tive cohort study is usually lower evidence than the randomized
controlled trials because a retrospective cohort study is subject
to have many unknown or uncontrolled confounding factors.
Further study is needed to evaluate the association between
hydrophilic and lipophilic statin.
Limitations
The retrospective cohort study is usually lower evidence than
the randomized controlled trials because a retrospective cohort
study is subject to have many unknown or uncontrolled con-
founding factors. Another limitation of our study was that car-
diovascular diseases are asymptomatic or underdiagnosed.
Based on the NHIRD, we could not collect patients’ other risk
factors for cardiovascular events such as lifestyle, alcohol con-
sumption, salt intake, nutritional status, weight and height, and
smoking habit. Because of the lack of individual laboratory
data (such as cholesterol, LDL or high-density lipoprotein,
fasting blood sugar, or hemoglobin A1C [HbA1C]) and for the
study subjects in the NHIRD, we did not do analyses of the
cholesterol reduction after different statin treatments and mea-
sures of diabetes (eg, fasting blood glucose or HbA1C) between
these subgroups. Image data such as radiologic results or heart
echo finding were also not offered by NHIRD. Of course, if the
patient could absolutely follow these doctors’ order to regularly
receive the statin therapy (patient compliance) should be con-
sidered as one of the other study limitations for this study.
Conclusion
Hydrophilic and lipophilic statin therapy for dyslipidemia is
still controversial in clinical practice. According to our long-
term cohort study, hydrophilic statin use may be a better choice
than lipophilic statin to reduce cardiovascular events in Asian
diabetic patients.
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